Lymphocytic Colitis: The Condition Your Colonoscopy Can't See
Lymphocytic colitis (LC) is a form of microscopic colitis, meaning the inflammation only shows up under a microscope. It typically strikes middle-aged to older adults, with a median age around 59 to 67 years, and is more common in women. The hallmark is chronic, watery, non-bloody diarrhea, often accompanied by abdominal pain, weight loss, and sometimes fecal incontinence. It can significantly affect quality of life even though it carries a largely benign prognosis.
Why a Normal Colonoscopy Doesn't Rule It Out
This is the single most important thing to understand about LC. The colon looks normal or near-normal during endoscopy. The diagnosis depends entirely on biopsy, which reveals a specific pattern: 20 to 30 or more intraepithelial lymphocytes (a type of immune cell) per 100 surface epithelial cells, increased inflammation in the lamina propria (the tissue layer just beneath the surface), and minimal distortion of the crypt architecture. Crucially, there is no thickened collagen band, which is what distinguishes LC from its sibling condition, collagenous colitis.
If you've had chronic watery diarrhea and a colonoscopy that came back "clean" with no biopsies taken, the possibility of microscopic colitis hasn't actually been excluded.
It Mimics IBS, and That's a Problem
LC can look a lot like irritable bowel syndrome (IBS) from the outside: chronic diarrhea, abdominal discomfort, urgency. The research notes that biomarkers such as increased colonic chromogranin A-positive cells may help distinguish LC from IBS, but in practice, the distinction often comes down to whether biopsies were taken during colonoscopy.
This matters because the treatments differ. IBS management strategies won't address the underlying mucosal immune response driving LC.
What Triggers It
LC appears to result from an abnormal immune response to something passing through the gut in people who are genetically susceptible. Several categories of triggers and associations emerge from the research:
Medications linked to LC:
- NSAIDs
- PPIs (proton pump inhibitors)
- SSRIs (selective serotonin reuptake inhibitors)
- Ticlopidine
- Flutamide
Associated conditions:
- Celiac disease
- Thyroid disease
- Diabetes
- Other autoimmune disorders
- Family history of inflammatory bowel disease or celiac disease
Infections may also play a role in precipitating or unmasking LC, though the research describes this as a possibility rather than a certainty. The medication connection is particularly worth noting because stopping the offending drug is often the first and most effective step in treatment.
The Three Paths LC Tends to Take
Not everyone with LC follows the same trajectory. The research describes three general patterns:
| Course | Approximate Frequency | What It Looks Like |
|---|---|---|
| Single self-limited attack | ~60% of adults | One episode that resolves, often within months to a few years |
| Chronic intermittent | ~30% of adults | Flares that come and go over time |
| Chronic continuous | A minority | Persistent symptoms requiring ongoing management |
Most adults achieve both symptom and histologic resolution (meaning the microscopic inflammation actually clears) over several years. That majority-remission pattern is genuine, but the roughly 30% who deal with recurring flares shouldn't be dismissed. Chronic intermittent LC is common enough that a plan for managing relapses matters.
Budesonide Works, But Relapse Is the Norm
Treatment follows a logical sequence. The first move is identifying and removing any medication that might be causing or worsening LC. After that, antidiarrheal agents like loperamide or diphenoxylate can help manage symptoms.
For more active disease, budesonide (a locally-acting steroid) is the best-supported therapy. It produces high short-term response rates. The problem: relapse is frequent once you stop taking it. This is the central tension in LC treatment. Budesonide controls symptoms effectively, but it often doesn't produce lasting remission after a single course.
| Treatment | Role | Key Consideration |
|---|---|---|
| Stop offending drugs | First step, always | NSAIDs, PPIs, SSRIs are common culprits |
| Loperamide / diphenoxylate | Symptom control | Useful for mild cases or as adjunct |
| Budesonide | Best-supported active treatment | High response rate, but frequent relapse on withdrawal |
| Bismuth, 5-ASA, cholestyramine | Second-line, empiric use | Less evidence than budesonide |
| Systemic steroids | Used empirically | Not first choice given budesonide's local action |
| Upadacitinib (advanced agent) | Refractory cases | Only a case report; rare to need this |
Truly refractory LC is rare. For those few patients who don't respond to standard approaches, emerging options like upadacitinib (reported in a single case) exist, but the evidence base is thin.
LC vs. Collagenous Colitis: Siblings, Not Twins
Both fall under the microscopic colitis umbrella and share the same core symptom of chronic watery diarrhea. But they differ in meaningful ways.
| Feature | Lymphocytic Colitis | Collagenous Colitis |
|---|---|---|
| Key biopsy finding | Increased intraepithelial lymphocytes, no thickened collagen band | Thickened subepithelial collagen band |
| Typical age at presentation | Tends to present earlier | Tends to present later |
| Disease severity | Generally milder | Can be more persistent |
| Resolution rate | More frequent spontaneous resolution | Less frequent spontaneous resolution |
Some risk factors and prognostic features differ between the two as well. This isn't just an academic distinction: if you've been diagnosed with one, knowing which type you have helps set realistic expectations about course and treatment.
A Different Story in Children
LC in children is rarer and appears to behave differently. In pediatric cases, LC is more often linked to immune dysregulation or underlying genetic defects. Symptoms may persist longer, and histologic remission (clearance of the microscopic inflammation) is less common than in adults. The research suggests that pediatric LC may carry a different risk profile altogether, so adult prognosis data shouldn't be directly applied to children.
Molecular Subtypes Hint at the Future
Recent transcriptomic work (studies examining which genes are active in affected tissue) suggests LC may not be a single disease. Researchers have identified what appear to be two subtypes: a channelopathic subtype driven by disruptions in ion and water transport, and an inflammatory subtype with distinct immune activation patterns and differences in microRNA regulation.
This is early-stage science, not something that changes clinical decisions today. But it matters because it could eventually explain why some people relapse repeatedly while others resolve quickly, and it may open the door to treatments targeted at the specific biology driving an individual's disease.
A Practical Framework If You Suspect LC
The research points to a clear sequence of priorities:
- If you have chronic watery diarrhea and a "normal" colonoscopy without biopsies, the diagnosis hasn't been excluded. Biopsies are essential.
- Review your medication list. NSAIDs, PPIs, and SSRIs are common enough that many people with LC are taking at least one.
- Screen for associated conditions. Celiac disease, thyroid disorders, and diabetes overlap with LC frequently enough to warrant checking.
- If treatment is needed beyond stopping a culprit drug, budesonide has the strongest evidence, but expect to discuss a plan for potential relapse.
- Take the long view. The majority of adults with LC see resolution over time. A diagnosis of LC is not a diagnosis of lifelong disease for most people, though roughly a third will deal with intermittent flares that need management.
